Ovid Therapeutics Inc
NASDAQ:OVID
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (125.8), the stock would be worth $7.01 (154% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 49.5 | $2.76 |
0%
|
| 3-Year Average | 125.8 | $7.01 |
+154%
|
| 5-Year Average | 87.4 | $4.87 |
+77%
|
| Industry Average | 6.7 | $0.38 |
-86%
|
| Country Average | 2.4 | $0.14 |
-95%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$286.4m
|
/ |
Jan 2026
$7.3m
|
= |
|
|
$286.4m
|
/ |
Dec 2026
$230.8k
|
= |
|
|
$286.4m
|
/ |
Dec 2027
$275.4k
|
= |
|
|
$286.4m
|
/ |
Dec 2028
$239.7k
|
= |
|
|
$286.4m
|
/ |
Dec 2029
$10.9m
|
= |
|
|
$286.4m
|
/ |
Dec 2030
$49.8m
|
= |
|
|
$286.4m
|
/ |
Dec 2031
$246.1m
|
= |
|
|
$286.4m
|
/ |
Dec 2032
$583.9m
|
= |
|
|
$286.4m
|
/ |
Dec 2033
$808.8m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Ovid Therapeutics Inc
NASDAQ:OVID
|
350.2m USD | 49.5 | -20.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 6.1 | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 5.1 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 5.5 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 9 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 5.2 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 2.7 | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Ovid Therapeutics Inc
Glance View
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2017-05-05. The firm is focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. The Company’s programs include OV329 (GABA aminotransferase inhibitor), OV350, OV882, and OV815 and OV825. OV329 (GABA aminotransferase inhibitor) is a next-generation GABA aminotransferase inhibitor being developed for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV329 functions by substantially reducing the activity of GABA aminotransferase (GABA-AT), a key enzyme responsible for the degradation of the brain’s major inhibitory neurotransmitter, GABA. OV350 is a small molecule that directly activates the KCC2 transporter, which is an important channel in seizure control. OV882, which is a short hairpin RNA (shRNA-551) for Angelman syndrome. OV815, which is a genetic therapy approach for KIF1A-associated neurological disorders.
